Summary
Thermo Fisher Scientific Inc. (TMO) reported strong performance in its 2021 fiscal year, marked by significant revenue growth and an expanding business scope, notably through strategic acquisitions. The company, a leader in serving science, demonstrated resilience and adaptability, particularly in supporting the global response to the COVID-19 pandemic with essential diagnostic and therapeutic products and services. The acquisition of PPD, Inc. in December 2021 significantly bolstered the company's Biopharma Services capabilities, enhancing its end-to-end offering for pharmaceutical and biotechnology clients. This, along with other strategic acquisitions and continued organic growth across its four key segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services – positions TMO for continued expansion. The company's diversified business model and commitment to innovation remain central to its strategy for driving growth and addressing complex scientific and healthcare challenges.
Financial Highlights
56 data points| Revenue | $39.21B |
| R&D Expenses | $1.41B |
| SG&A Expenses | $8.01B |
| Operating Expenses | $29.18B |
| Operating Income | $10.03B |
| Interest Expense | $536.00M |
| Net Income | $7.73B |
| EPS (Basic) | $19.62 |
| EPS (Diluted) | $19.46 |
| Shares Outstanding (Basic) | 394.00M |
| Shares Outstanding (Diluted) | 397.00M |
Key Highlights
- 1Thermo Fisher Scientific achieved substantial revenue growth in 2021, increasing by 22% to $39.21 billion, driven by strong performance across all end markets and significant contributions from COVID-19 related products and services.
- 2The company completed the transformative acquisition of PPD, Inc. for $15.99 billion, significantly expanding its clinical research services capabilities within the Laboratory Products and Biopharma Services segment.
- 3Organic revenue growth was robust at 17%, demonstrating the company's underlying business strength beyond acquisitions and currency impacts, with particular strength noted in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
- 4The Life Sciences Solutions segment saw a significant revenue increase of 28% (organic growth of 23%), driven by demand for COVID-19 diagnostics, biosciences products, and bioproduction capabilities supporting vaccine and therapy manufacturing.
- 5The company reported strong profitability with GAAP operating income increasing by 29% to $10.03 billion and adjusted operating income increasing by 27% to $12.14 billion, leading to a 28% increase in adjusted EPS to $25.13.
- 6Strategic investments in innovation and commercial capabilities, alongside productivity improvements, contributed to an expansion in operating income margins across most segments.
- 7The company generated substantial free cash flow of $6.81 billion, supporting its capital allocation strategy which includes strategic acquisitions, share repurchases, and dividends.